Cubist Systematic Strategies’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-168,738
| Closed | -$614K | – | 2970 |
|
|
2025
Q2 | $614K | Buy |
168,738
+160,903
| +2,054% | +$442K | ﹤0.01% | 2168 |
|
|
2025
Q1 | $15K | Buy |
+7,835
| New | +$16K | ﹤0.01% | 2754 |
|
|
2024
Q2 | – | Sell |
-398,247
| Closed | -$729K | – | 2904 |
|
|
2024
Q1 | $729K | Buy |
398,247
+330,620
| +489% | +$529K | ﹤0.01% | 2386 |
|
|
2023
Q4 | $83.9K | Buy |
+67,627
| New | +$69K | ﹤0.01% | 3211 |
|
|
2023
Q1 | – | Sell |
-11,232
| Closed | -$6.48K | – | 3858 |
|
|
2022
Q4 | $6.48K | Buy |
+11,232
| New | +$3.52K | ﹤0.01% | 4074 |
|
|
2022
Q3 | – | Sell |
-18,295
| Closed | -$6K | – | 4394 |
|
|
2022
Q2 | $6K | Buy |
+18,295
| New | +$7.68K | ﹤0.01% | 4288 |
|
|
2022
Q1 | – | Sell |
-158,507
| Closed | -$358K | – | 3535 |
|
|
2021
Q4 | $358K | Buy |
158,507
+99,227
| +167% | +$271K | ﹤0.01% | 2680 |
|
|
2021
Q3 | $171K | Sell |
59,280
-65,195
| -52% | -$186K | ﹤0.01% | 2627 |
|
|
2021
Q2 | $472K | Buy |
124,475
+65,415
| +111% | +$220K | 0.01% | 2055 |
|
|
2021
Q1 | $200K | Buy |
59,060
+34,143
| +137% | +$123K | ﹤0.01% | 2478 |
|
|
2020
Q4 | $70K | Sell |
24,917
-8,342
| -25% | -$24.4K | ﹤0.01% | 2438 |
|
|
2020
Q3 | $83K | Sell |
33,259
-59,441
| -64% | -$522K | ﹤0.01% | 2312 |
|
|
2020
Q2 | $1.26M | Buy |
92,700
+22,094
| +31% | +$229K | 0.02% | 1055 |
|
|
2020
Q1 | $535K | Buy |
70,606
+18,771
| +36% | +$146K | 0.01% | 1215 |
|
|
2019
Q4 | $328K | Buy |
+51,835
| New | +$246K | 0.01% | 1802 |
|
|
2019
Q3 | – | Sell |
-61,000
| Closed | -$295K | – | 2190 |
|
|
2019
Q2 | $295K | Sell |
61,000
-8,010
| -12% | -$45.6K | 0.01% | 1813 |
|
|
2019
Q1 | $565K | Buy |
69,010
+15,626
| +29% | +$107K | 0.02% | 1113 |
|
|
2018
Q4 | $295K | Buy |
53,384
+51,855
| +3,391% | +$406K | 0.01% | 1288 |
|
|
2018
Q3 | $14K | Sell |
1,529
-12,204
| -89% | -$109K | ﹤0.01% | 1807 |
|
|
2018
Q2 | $137K | Sell |
13,733
-2,853
| -17% | -$28.6K | 0.01% | 1457 |
|
|
2018
Q1 | $158K | Buy |
+16,586
| New | +$232K | 0.01% | 1484 |
|
|
2017
Q3 | – | Sell |
-11,038
| Closed | -$159K | – | 1825 |
|
|
2017
Q2 | $159K | Buy |
+11,038
| New | +$140K | 0.01% | 1353 |
|
|
2016
Q3 | – | Sell |
-694
| Closed | -$5K | – | 1679 |
|
|
2016
Q2 | $5K | Sell |
694
-1,911
| -73% | -$16.7K | ﹤0.01% | 1669 |
|
|
2016
Q1 | $23K | Sell |
2,605
-24,916
| -91% | -$202K | ﹤0.01% | 1521 |
|
|
2015
Q4 | $356K | Buy |
+27,521
| New | +$281K | 0.02% | 1014 |
|
Other funds holding AKBA
MB
Cubist Systematic Strategies's AKBA Position: Q3 2025 in Review
Cubist Systematic Strategies sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 168,738 shares — an estimated $614K sold.
Cubist Systematic Strategies first reported a position in AKBA in Q4 2015 and held it in 25 quarters. The position peaked at $1.26M in Q2 2020. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.
- Cubist Systematic Strategies reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 168,738 Akebia Therapeutics shares in Q3 2025, an estimated $614K.
- Cubist Systematic Strategies first reported a position in Akebia Therapeutics in Q4 2015 and held it in 25 quarters.
- Cubist Systematic Strategies's Akebia Therapeutics position peaked at $1.26M in Q2 2020.
- 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.